885692-52-4

Basic information

• Product Name: JNJ-28312141
• Synonyms: JNJ-28312141;JNJ-28312141(JNJ-141);4-Cyano-N-(5-(1-(2-(dimethylamino)acetyl)piperidin-4-yl)-2',3',4',5'-tetrahydro-[1,1'-biphenyl
• CAS NO: 885692-52-4
• Molecular Formula: C₂₆H₃₂N₆O₂
• Molecular Weight: 460.58
• Mol File: 885692-52-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.27±0.1 g/cm3(Predicted)
• PKA: 7.30±0.10(Predicted)
• CAS DataBase Reference: JNJ-28312141(CAS DataBase Reference)
• NIST Chemistry Reference: JNJ-28312141(885692-52-4)
• EPA Substance Registry System: JNJ-28312141(885692-52-4)

Safety Data

• Hazardous Substances Data: 885692-52-4(Hazardous Substances Data)

Usage

General Description

JNJ-28312141 is a selective and potent antagonist of the orexin-2 receptor (OX2R) and has been studied for its potential in treating sleep disorders such as insomnia and narcolepsy. It has been shown to reduce wakefulness and promote sleep in animals, making it a promising candidate for the development of medications to regulate sleep-wake cycles. Additionally, JNJ-28312141 has been investigated for its potential in treating addiction and other neurobehavioral disorders, as it affects the activity of the orexin system, which plays a role in regulating reward and motivation. Further research is needed to fully explore the potential therapeutic applications of this compound.

Upstream product

• 1118-68-9 dimethylaminoacetic acid 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 885693-02-7 (4-{[4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carbon-yl]-amino}-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 885693-01-6 4-(4-amino-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 885693-00-5 4-(4-amino-3-bromophenyl)piperidine-1-carboxylic acid tert-butyl ester 
• 170011-57-1 tert-butyl 4-(4-aminophenyl)piperidin-1-carboxylate 
• 873454-43-4 4-(4-aminophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 60853-81-8 N,N-dimethylaminoacetyl chloride hydrochloride 
• 108-24-7 acetic anhydride 

Relevant articles and documents

POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION

Positron emission tomography (PET) radiotracers for imaging macrophage colony stimulating factor-1 receptors in a subject afflicted with or suspected of being afflicted with a neuroinflammatory or neurodegenerative disease or disorder are disclosed.

METHOD OF INHIBITING C-KIT KINASE

A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formula (I): wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided.